ZA201706612B - Fused bicyclic heteroaryl derivatives having activity as phd inhibitors - Google Patents

Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Info

Publication number
ZA201706612B
ZA201706612B ZA2017/06612A ZA201706612A ZA201706612B ZA 201706612 B ZA201706612 B ZA 201706612B ZA 2017/06612 A ZA2017/06612 A ZA 2017/06612A ZA 201706612 A ZA201706612 A ZA 201706612A ZA 201706612 B ZA201706612 B ZA 201706612B
Authority
ZA
South Africa
Prior art keywords
activity
bicyclic heteroaryl
fused bicyclic
heteroaryl derivatives
phd inhibitors
Prior art date
Application number
ZA2017/06612A
Other languages
English (en)
Inventor
Ahmed Saleh
Barker Gregory
Canning Hannah
Davenport Richard
Harrison David
Jenkins Kerry
Livermore David
Wright Susanne
Kinsella Natasha
Original Assignee
Takeda Pharmaceutical Company Ltd A Japanese Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Ltd A Japanese Company filed Critical Takeda Pharmaceutical Company Ltd A Japanese Company
Publication of ZA201706612B publication Critical patent/ZA201706612B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2017/06612A 2015-03-18 2017-10-02 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors ZA201706612B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds
PCT/JP2016/059782 WO2016148306A1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Publications (1)

Publication Number Publication Date
ZA201706612B true ZA201706612B (en) 2019-01-30

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/06612A ZA201706612B (en) 2015-03-18 2017-10-02 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Country Status (31)

Country Link
US (1) US10287286B2 (enExample)
EP (1) EP3271357B1 (enExample)
JP (1) JP6726681B2 (enExample)
KR (1) KR102609431B1 (enExample)
CN (1) CN107531698B (enExample)
AU (1) AU2016234209B2 (enExample)
BR (1) BR112017019653B1 (enExample)
CA (1) CA2979024C (enExample)
CL (1) CL2017002354A1 (enExample)
CO (1) CO2017009353A2 (enExample)
CR (1) CR20170468A (enExample)
DK (1) DK3271357T3 (enExample)
DO (1) DOP2017000209A (enExample)
EA (1) EA035739B1 (enExample)
EC (1) ECSP17069696A (enExample)
ES (1) ES2774052T3 (enExample)
GB (1) GB201504565D0 (enExample)
GE (1) GEP20207095B (enExample)
HU (1) HUE047918T2 (enExample)
IL (1) IL254277B (enExample)
MX (1) MX2017011902A (enExample)
MY (1) MY194873A (enExample)
NZ (1) NZ735631A (enExample)
PE (1) PE20180656A1 (enExample)
PH (1) PH12017501699B1 (enExample)
PT (1) PT3271357T (enExample)
SG (1) SG11201707280VA (enExample)
TN (1) TN2017000384A1 (enExample)
UA (1) UA123668C2 (enExample)
WO (1) WO2016148306A1 (enExample)
ZA (1) ZA201706612B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3419978T2 (ro) 2016-02-24 2020-07-31 Pfizer Derivaţi de pirazolo[1,5-a]pirazin-4-il
WO2019034973A1 (en) 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
SG11202102441VA (en) * 2018-09-13 2021-04-29 Kissei Pharmaceutical Co Ltd Imidazopyridinone compound
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
CN117304171A (zh) * 2020-04-20 2023-12-29 深圳市塔吉瑞生物医药有限公司 吡嗪取代的烟酰胺的固体形式及其制备和用途
WO2022083569A1 (en) * 2020-10-20 2022-04-28 Amgen Inc. Heterocyclic spiro compounds and methods of use
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
US20250034132A1 (en) 2021-10-28 2025-01-30 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
CN118715015A (zh) * 2021-12-17 2024-09-27 阿克比治疗有限公司 选择性phd1抑制剂化合物、组合物和使用方法
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
EA006483B1 (ru) 2000-06-30 2005-12-29 Уайт Замещенные триазолопиримидины в качестве противораковых средств
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
US8283465B2 (en) * 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
JP2011168582A (ja) 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
WO2014030716A1 (ja) * 2012-08-23 2014-02-27 田辺三菱製薬株式会社 ピラゾロピリミジン化合物

Also Published As

Publication number Publication date
CL2017002354A1 (es) 2018-05-04
WO2016148306A1 (en) 2016-09-22
HK1249512A1 (en) 2018-11-02
ES2774052T3 (es) 2020-07-16
CO2017009353A2 (es) 2017-11-30
MX2017011902A (es) 2017-12-15
UA123668C2 (uk) 2021-05-12
CA2979024A1 (en) 2016-09-22
GB201504565D0 (en) 2015-05-06
BR112017019653A2 (pt) 2018-05-15
CN107531698B (zh) 2024-08-13
PT3271357T (pt) 2020-02-21
IL254277B (en) 2020-10-29
BR112017019653B1 (pt) 2023-10-03
MY194873A (en) 2022-12-21
GEP20207095B (en) 2020-04-10
EA035739B1 (ru) 2020-08-03
AU2016234209A1 (en) 2017-10-12
CR20170468A (es) 2018-04-27
DK3271357T3 (da) 2020-02-17
CN107531698A (zh) 2018-01-02
KR20170129874A (ko) 2017-11-27
JP2018512408A (ja) 2018-05-17
AU2016234209B2 (en) 2020-08-27
PE20180656A1 (es) 2018-04-17
IL254277A0 (en) 2017-10-31
JP6726681B2 (ja) 2020-07-22
HUE047918T2 (hu) 2020-05-28
TN2017000384A1 (en) 2019-01-16
PH12017501699B1 (en) 2023-06-30
KR102609431B1 (ko) 2023-12-04
ECSP17069696A (es) 2018-02-28
PH12017501699A1 (en) 2018-03-12
EA201792057A1 (ru) 2018-04-30
US20180072714A1 (en) 2018-03-15
EP3271357A1 (en) 2018-01-24
US10287286B2 (en) 2019-05-14
DOP2017000209A (es) 2017-10-15
CA2979024C (en) 2024-02-20
EP3271357B1 (en) 2019-11-27
NZ735631A (en) 2023-07-28
SG11201707280VA (en) 2017-10-30

Similar Documents

Publication Publication Date Title
ZA201706612B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
IL256808A (en) Heteroaryl derivatives as parp inhibitors
IL246140A0 (en) History of bicyclic heterocyclics as bromodomain repressors
ZA201801032B (en) Bicyclic compounds as atx inhibitors
IL253691A0 (en) Bicyclic heterocyclics as fgfr inhibitors
IL253869A0 (en) Bicyclic heterocyclics as fgfr4 inhibitors
ZA201800480B (en) New bicyclic compounds as dual atx/ca inhibitors
IL255570A (en) Bicyclic compounds as atx inhibitors
SI3371190T1 (sl) Heterociklične spojine kot inhibitorji PI3K gama
SG11201706729SA (en) Derivatives of sobetirome
IL253588A0 (en) History of bicyclic quinazolinones
IL255511B (en) New bicyclic compounds as dual atx/ca inhibitors
EP3323809A4 (en) Bicyclic heterocyclic amide derivative
IL255357A0 (en) bicyclic compounds
EP3275874A4 (en) Fused heterocyclic compound
ZA201706038B (en) Bicyclic pyridine compound